Methods of treatment using CTLA4 mutant molecules
US9758565B2 · kind B2 · utility
5Cited by
35References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 29, 2014 |
| Grant date | Sep 12, 2017 |
| Priority date | — |
| Expiry date | Feb 20, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/51
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.